DANIEL GILLETTE: Open Payments
NPI 1053376475 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$44,115 in 82 payments from 13 companies in 2025. Trend: 2023 $708 · 2024 $999 · 2025 $44,115
Honoraria: $40,350Travel & lodging: $2,396Food & beverage: $1,369
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 50 | $29,898 |
| MDD US Operations, LLC | 10 | $13,797 |
| E.R. Squibb & Sons, L.L.C. | 3 | $89 |
| Lundbeck LLC | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Neurocrine BioSciences, Inc. | 2 | $33 |
| Janssen Pharmaceuticals, Inc | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
Products named: Qelbree, REXULTI, COBENFY, CAPLYTA, AUSTEDO XR, INGREZZA, HETLIOZ, ARISTADA.
Industry payments across IA — which companies pay providers there.
